Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a structurally unique, potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively. Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. FK228 (Romidepsin) treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. FK228(Romidepsin) is currently in a Phase I study in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.<span style='color:#ff0000;'><strong>*The compound is unstable in solutions, freshly prepared is recommended</strong></span>
Nat Commun. 2019 Dec 20;10(1):5799.
Novel approach reveals genomic landscapes of single-strand DNA breaks with nucleotide resolution in human cells.
Romidepsin (FK228) purchased from AbMole
|Solubility (25°C)||DMSO 10 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Coiffier B, et al. J Clin Oncol. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
 Piekarz RL, et al. Blood. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
|Related HDAC Products|
Psammaplin A is a Marine metabolite that acts as a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A is a highly selective HDAC1 inhibitor with an IC50 of 0.9 nM, which is 360 times more selective to HDAC1 than DAC6 and more than 1000 times less potent to HDAC7 and HDAC8.
|FNDR-20123 free base
FNDR-20123 free base is an effective, safe and first-in-class anti-malarial HDAC inhibitor with an IC50 of 31 nM for Plasmodium and 3 nM for human HDAC.
FNDR-20123 is an effective, safe and first-in-class anti-malarial HDAC inhibitor with IC50 of 31 nM for Plasmodium and 3 nM for human HDAC.
GSK3117391 (GSK3117391A, HDAC-IN-3) is a potent histone deacetylase (HDAC) inhibitor.
|Tubastatin A TFA
Tubastatin A TFA (Tubastatin A trifluoroacetate salt) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.